Biopharma Industry: Trump's Executive Order Could Help Innovation, but Range of Scenarios Still Open | Morningstar

Biopharma Industry: Trump’s Executive Order Could Help Innovation, but Range of Scenarios Still Open
We’re not changing any valuations or ratings as a result of the order, which was light on detail.
Editor’s Note: This analysis was original
Read more...